33 results
Page 2 of 2
8-K
EX-2.1
ltbbs8qcwi vd
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
425
EX-2.1
9bdrztm8fvyx
29 Mar 21
Business combination disclosure
7:27am
8-K
EX-99.1
68sf f8z6sm
5 Jan 21
Millendo Therapeutics Provides Pipeline and Business Update
9:08am
8-K
EX-99.1
qkrn dwz8g308qmyaz
24 Sep 20
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
8:33am
8-K
EX-99.1
k46w4
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am
8-K
EX-99.2
3ebia5eca hkpjcf
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am
8-K
EX-99.1
tpf1fnhre3 vnbhxt3
6 Apr 20
Cost Associated with Exit or Disposal Activities
7:16am
8-K
i23kr 3ka
6 Apr 20
Cost Associated with Exit or Disposal Activities
7:16am